Indeed, the blockade of PD1/PD-L1 by administering anti-PD1, or anti-PD-L1, has been demonstrated to be effective in patients with non-small cell lung cancer (NSCLC) [26, 27]. Here, CD274 is linked to non-small cell lung carcinoma.